linezolid + vancomycin
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Skin/Soft Tissue Infections
Conditions
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Trial Timeline
Oct 1, 2004 → Jul 1, 2007
NCT ID
NCT00087490About linezolid + vancomycin
linezolid + vancomycin is a approved stage product being developed by Pfizer for Skin/Soft Tissue Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00087490. Target conditions include Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA).
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01561469 | Pre-clinical | Completed |
| NCT00087490 | Approved | Completed |
| NCT00035425 | Phase 3 | Completed |